Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
News Jun 02, 2014
Monitoring the levels of these markers may be useful in predicting the response to therapy for Type 2 diabetes.
Nuclea has extensive experience in developing and commercializing biomarkers and clinical tests. The Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully collaborated with numerous leading clinical researchers to apply mass spectrometry (MS) to biomarker discovery and its translation to high-throughput, quantitative methods.
“We’ve already worked with the BRIMS Center to develop two other very important assays,” said Nuclea CEO, Patrick Muraca. “These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins.”
“The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area.” said Mary Lopez, director of the BRIMS Center, Thermo Fisher Scientific. “Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts.”
Scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations. A proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software will be used for the collaborative work.
Have you ever been stressed out by the idea of doing math or statistics problems? You’re not alone. A new study has used a questionnaire and an analytical technique called "network science" to determine precisely what factors contribute to this kind of statistics anxiety among psychology majors.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019